Another study of patients with stage II to IV lung cancer (n = 67, the majority with NSCLC) evaluated the association between changes in the ratio of plasma CXCL10 to IL-8 after treatment with nivolumab or pembrolizumab combined with chemotherapy [43]. This evidence concerns the gene CXCL10 and non-small cell lung carcinoma.